Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia (301)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Celator Pharmaceuticals
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Celator Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01696084
First received: September 26, 2012
Last updated: September 5, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)